FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes

BRIDGEWATER, N.J. and THE WOODLANDS, Texas, May 22, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve...

from PR Newswire: https://ift.tt/2J4pdrw
via